IKT (STOCKS)
Inhibikase Therapeutics, Inc. Common Stock
$1.717200
+0.117200 (+7.33%)
Prev close: $1.600000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Mark T. Iwicki
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $206.15M
- Employees
- 16
- P/E (TTM)
- -3.00
- P/B (TTM)
- 1.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $51.13M |
| Selling, General, and Administrative Expenses | $22.52M |
| Research and Development | $30.63M |
| Operating Income/Loss | -$51.13M |
| Income/Loss From Continuing Operations After Tax | -$47.66M |
| Income/Loss From Continuing Operations Before Tax | -$51.13M |
| Interest Income/Expense After Provision For Losses | $3.47M |
| Interest Income/Expense Operating, Net | $3.47M |
| Net Income/Loss | -$47.66M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$47.66M |
| Net Income/Loss Available To Common Stockholders, Basic | -$47.66M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | $0.48 |
| Diluted Earnings Per Share | $0.48 |
| Basic Average Shares | 195,945,793 |
| Diluted Average Shares | 195,945,793 |
| Assets | $79.59M |
| Current Assets | $78.54M |
| Prepaid Expenses | $210.57K |
| Other Current Assets | $78.33M |
| Noncurrent Assets | $1.06M |
| Fixed Assets | $0.00 |
| Non-current Prepaid Expenses | $1.00M |
| Other Non-current Assets | $57.91K |
| Liabilities | $6.70M |
| Current Liabilities | $6.70M |
| Accounts Payable | $620.53K |
| Other Current Liabilities | $6.08M |
| Noncurrent Liabilities | $0.00 |
| Equity | $72.90M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $72.90M |
| Liabilities And Equity | $79.59M |
| Net Cash Flow From Operating Activities | -$25.62M |
| Net Cash Flow From Operating Activities, Continuing | -$25.62M |
| Net Cash Flow From Investing Activities | -$36.61M |
| Net Cash Flow From Investing Activities, Continuing | -$36.61M |
| Net Cash Flow From Financing Activities | $99.58M |
| Net Cash Flow From Financing Activities, Continuing | $99.58M |
| Net Cash Flow | $37.36M |
| Net Cash Flow, Continuing | $37.36M |
| Other Comprehensive Income/Loss | -$47.66M |